Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/21/2013WO2013173206A1 Phosphonate derivatives for treatment of alzheimer's disease
11/21/2013WO2013173198A1 Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
11/21/2013WO2013173180A2 Histatin for corneal wound healing and ocular surface disease
11/21/2013WO2013173096A2 Conjugates of huperzine and analogs thereof
11/21/2013WO2013172999A1 Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
11/21/2013WO2013172923A1 Uses of antagonists of hyaluronan signaling
11/21/2013WO2013172872A1 Pyrimidine diamine derivatives as inhibitors of cytosolic hsp90
11/21/2013WO2013172805A1 New orodispersible tablet formulations of olanzapine
11/21/2013WO2013172732A1 Complex compounds of germanium, methods for producing same, and drugs
11/21/2013WO2013172725A1 The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses
11/21/2013WO2013172714A1 Treatment of conditions associated with mycotoxin exposure
11/21/2013WO2013172682A1 Use of flavone compound for prevention or treatment of obesity
11/21/2013WO2013172681A1 Use of kaempferia parviflora wall. ex. baker extracts or flavone compound for preventing or treating muscle diseases, or improving muscle function
11/21/2013WO2013172640A1 Composition having heat shock protein induction activity and comprising compound isolated from eucommia ulmoides
11/21/2013WO2013172537A1 Pharmaceutical composition for treating or preventing neurological disorders caused by alcohol exposure during pregnancy, containing metformin and/or thymoquinone
11/21/2013WO2013172528A1 Novel use for asterubin
11/21/2013WO2013172479A1 Carboxylic acid compounds
11/21/2013WO2013172436A1 Novel glycosylated compound of crocin, method for producing same, and use for same
11/21/2013WO2013172346A1 Highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester with reduced environmental pollutants, and method for producing same
11/21/2013WO2013172344A1 Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity c-reactive protein
11/21/2013WO2013172339A1 Prophylactic agent and/or therapeutic agent for stress urinary incontinence
11/21/2013WO2013172297A1 Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative
11/21/2013WO2013171763A1 Ready to be infused gemcitabine solution
11/21/2013WO2013171756A1 Amorphous form of linagliptin and process for preparation thereof
11/21/2013WO2013171726A1 Non-ionic vesicle formulations of calcium channel blockers
11/21/2013WO2013171712A1 Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease
11/21/2013WO2013171694A1 Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
11/21/2013WO2013171690A1 Monocyclic heteroaryl cycloalkyldiamine derivatives
11/21/2013WO2013171687A1 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
11/21/2013WO2013171684A1 Progesterone receptor modulators for use in preventing or treating androgen mediated diseases
11/21/2013WO2013171642A1 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
11/21/2013WO2013171641A1 Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
11/21/2013WO2013171640A1 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
11/21/2013WO2013171639A1 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
11/21/2013WO2013171607A1 Vaginal cream for the treatment of papilloma infection comprising docosanol, turmeric, amla and aloe
11/21/2013WO2013171545A1 Commercial process for the recovery of phenolic compounds with antioxidant capacity from waste from the berry-processing industry
11/21/2013WO2013171473A1 Dosage regimen for sapacitabine and seliciclib
11/21/2013WO2013171470A1 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
11/21/2013WO2013171382A1 Docetaxel-based prolonged-release cancer treatment drug
11/21/2013WO2013171345A1 Tri-substituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
11/21/2013WO2013171334A1 Methanethione compounds having antiviral activity
11/21/2013WO2013171318A1 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists
11/21/2013WO2013171317A1 Pyrazole derivatives and their use as lpar5 antagonists
11/21/2013WO2013171316A1 Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
11/21/2013WO2013171307A1 N-methyl-4-benzylcarbamidopyridinium chloride and a process for its preparation
11/21/2013WO2013171289A1 Combination of cd37 antibodies with further agents
11/21/2013WO2013171281A1 Hydantoin and thiohydantoin derivatives as antiviral drugs
11/21/2013WO2013171258A1 Method of topically treating actinic keratosis with ingenol mebutate cycle therapy
11/21/2013WO2013171252A1 Means to facilitate food intake and food retention
11/21/2013WO2013171224A1 Radioactive rhodium complexes, preparation methods and uses thereof
11/21/2013WO2013171204A2 Ophthalmological vehicle system for medicaments, ophthalmological kit and use of an ophthalmological composition
11/21/2013WO2013171203A1 Fluid dispenser containing an ophthalmological composition
11/21/2013WO2013171167A1 A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
11/21/2013WO2013171166A1 A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
11/21/2013WO2013171164A1 Compositions and formulations for the treatment of halitosis
11/21/2013WO2013171159A1 Topical pharmaceutical compositions comprising terbinafine and urea
11/21/2013WO2013171157A1 Method for producing recombinant 11-de-o-methyltomaymycin
11/21/2013WO2013171146A1 Oral film containing enteric release opiate resinate
11/21/2013WO2013171100A1 Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors
11/21/2013WO2013171055A1 Method for the in vitro maturation of dendritic cells.
11/21/2013WO2013170985A1 New aminoglycoside antibiotics targeting bacterial 16s ribosomal rna lacking ototoxicity
11/21/2013WO2013170972A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant
11/21/2013WO2013170971A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar
11/21/2013WO2013170970A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam
11/21/2013WO2013170969A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol
11/21/2013WO2013170968A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro [cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
11/21/2013WO2013170967A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
11/21/2013WO2013170966A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a gabapentinoid
11/21/2013WO2013170965A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and antidepressants
11/21/2013WO2013170921A1 Combination therapy agent for treating rhinitis
11/21/2013WO2013170901A1 N-methyl-4-benzylcarbamidopyridinium chloride and a process for its preparation
11/21/2013WO2013170774A1 Acetylene derivative having antineoplastic activity
11/21/2013WO2013170770A1 Acetylene derivatives having antitumor activity
11/21/2013WO2013170761A1 Method for preparing pregnane derivative 16,17-acetal (ketal) compounds
11/21/2013WO2013170758A1 Fused ring-structured benzamide compound and application thereof as antineoplastic medicament
11/21/2013WO2013170757A1 4-aminoquinazoline hydroxamic acid compound and application as antineoplastic medicament
11/21/2013WO2013170756A1 Applications of dopac in preparing antitumor drugs
11/21/2013WO2013170741A1 Benzodioxane compound, composition comprising same and use thereof
11/21/2013WO2013170738A1 Agomelatine acid radical composite, and preparation method and application thereof
11/21/2013WO2013170719A1 Vinorelbine derivatives, pharmaceutical composition, preparation method therefor and application thereof
11/21/2013WO2013170711A1 Analgesic pharmaceutical composition
11/21/2013WO2013170694A1 Costunolide derivative, pharmaceutical composition thereof as well as preparation method and use thereof
11/21/2013WO2013170671A1 Pteridine ketone derivative and applications thereof as egfr, blk, and flt3 inhibitor
11/21/2013WO2013170656A1 Fluoroethyl thiamine or its salt and application thereof in preparing anticoccidial drugs
11/21/2013WO2013170655A1 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
11/21/2013WO2013170637A1 Application of paeoniflorin compound in preparation of antitumor drug
11/21/2013WO2013170386A1 Oligonucleotide chelate complex-polypeptide compositions and methods
11/21/2013WO2013170385A1 Oligonucleotide chelate complex methods
11/21/2013WO2013170379A1 Drug delivery across the blood-brain barrier using magnetically heatable entities
11/21/2013WO2013170367A1 Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
11/21/2013WO2013170365A1 Compositions of sparc polypeptide and grp78, and methods and uses thereof for sensitizing cancer cells
11/21/2013WO2013170317A1 Liquid formulation
11/21/2013WO2013170305A1 Cellular vaccine and method of inducing an immune response in a subject
11/21/2013WO2013149258A3 Compositions and methods for treating or preventing metabolic syndrome disorders
11/21/2013WO2013140417A4 BORONIC ACID BEARING LIPHAGANE COMPOUNDS AS INHIBITORS OF PI3K-α AND/OR β
11/21/2013WO2013138563A8 Glycomimetics to inhibit pathogen-host interactions
11/21/2013WO2013128419A3 Pharmaceutical compositions comprising boronic acid compounds
11/21/2013WO2013127782A3 Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart
11/21/2013WO2013119144A3 Hair growth agent (embodiments) and method for treating hair loss
11/21/2013WO2013117744A3 Methods of treating fibrosis
1 ... 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 ... 7860